GlobeNewswire

2024-09-02 12:47

CORRECTION: The Global Virus Network (GVN) Escalates MPOX Emergency Response Across Africa and Beyond

TAMPA, Fla., Sept. 02, 2024 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated on August 16th. Sten Vermund's full title was corrected to Sten Vermund, MD, PhD, GVN President and Professor of Yale University, USA. The complete and corrected release follows.

As the World Health Organization (WHO) declares MPOX a public health emergency of international concern, the Global Virus Network (GVN), headquartered at the University of South Florida (USF), USA, swiftly orchestrated an international response to combat the rising threat. The GVN's MPOX Action Committee, formed in 2022, is led by world experts spanning basic research, epidemiology, clinical research, and vaccines. In the past several weeks, the GVN has rapidly mobilized essential resources, launched critical evaluations of diagnostic tools, and provided strategic support to the most affected regions.

Sten Vermund, MD, PhD, GVN President and Professor of Yale University, USA, said, "MPOX is a reemerging disease whose magnitude is rising at an alarming rate among general populations in Africa. Furthermore, it has shown potential for sexually associated transmission worldwide. The GVN MPOX Action Committee is working with the WHO and international partners to craft an evidence-based response and further research agenda.”

Since last week's announcement that MPOX was reported in countries never previously identified with cases, the GVN partnered with the UK Health Security Agency (UKHSA) and multiple African institutions through its members to assess point-of-care (POC) tests for MPOX, ensuring these diagnostics are accurate, accessible, and deployable in various environments.

Emma Thomson, PhD, Professor of Infectious Diseases and Associate Director, Medical Research Council-University of Glasgow Centre for Virus Research, UK, a GVN Center of Excellence, added, "GVN’s coordinated response exemplifies the power of global collaboration in a public health crisis. We are proud to be part of a network that is helping to set priorities and making a real difference in the fight against MPOX. We look forward to working with the GVN, WHO, and other partners to mitigate this viral outbreak."

The GVN's MPOX Action Committee is co-led by Rachel Roper, PhD, Professor of Microbiology and Immunology at East Carolina University, USA, who expressed deep concern: "The MPOX virus appears to be evolving for more efficient human transmission, which is alarming. With 17,000 reported cases and the unprecedented spread of MPOX Clade Ib from the Democratic Republic of Congo (DRC) to neighboring countries, there is a clear need for heightened and continuous surveillance. We have vaccines that mitigate illness and death, but there is an urgent need for improved vaccines with better safety and efficacy."

Dr. Roper further emphasized the importance of therapeutics, stating, "We do have antibodies and treatments that offer some protection, but these viruses have already demonstrated the ability to rapidly develop resistance. It's critical that we expand the arsenal of therapeutic agents."

In addition to forming an MPOX Action Committee two years ago comprised of top experts, GVN's proactive measures include the deployment of 1,000 newly developed MPOX rapid tests several weeks ago to its members across Africa for immediate side-by-side evaluation. The network is also distributing new rapid test platforms for loop-mediated isothermal amplification (LAMP) assays to strategic locations, aiming to foster the development of diagnostics that can be efficiently implemented in resource-limited settings. Further, since 2022, GVN members published more than 70 scientific papers advancing MPOX research.

Laurens Liesenborghs, MD, PhD, an infectious disease specialist and researcher at the Institute of Tropical Medicine, Belgium, under the lead of Placide Mbala-Kingebeni, MD, PhD, Director of the Virology Division at the Institut National de Recherche Biomédicale (INRB), Democratic Republic of the Congo, together with others, was the first to investigate and sequence the newly identified MPOX Clade Ib variant.  Dr. Liesenborghs said, "Our team remains on-site, dedicated to conducting research, and supporting surveillance and patient care. Together, we continue to combat this evolving threat and ensure the health and safety of the affected communities. Support from the GVN, which we are receiving, and other partners, is needed to address this public health crisis swiftly."  Drs. Liesenborghs and Mbala-Kingebeni are members of the GVN MPOX Action Committee.

Maggie L. Bartlett, PhD, Program Director at GVN and virologist at Johns Hopkins Bloomberg School of Public Health, USA, a GVN Center of Excellence, said, “The ongoing challenges with MPOX underscore the urgent need for comprehensive global surveillance and targeted response strategies. By closely collaborating with WHO and other international partners, we ensure that our efforts are aligned and that our scientific contributions directly address the pressing challenges on the ground.”

MPOX has been detected in 13 nations this year including previously unaffected nations such as Burundi, Kenya, Rwanda, and Uganda. In 2024, thus far, The Africa Centers for Disease Control and Prevention (Africa CDC) reports that these countries have confirmed 2,863 cases and 517 deaths and growing, primarily in the Democratic Republic of the Congo (DRC). Suspected cases across the continent have surged past 17,000, a significant increase from 7,146 cases in 2022 and 14,957 cases in 2023. Officials at the Africa CDC said nearly 70% of cases in Congo are in children younger than 15, who also accounted for 85% of deaths.

GVN plays a crucial role in facilitating direct communication between its experts, WHO officials, and other international partners. Christian Bréchot, MD, PhD, Vice Chairman of the GVN Board of Directors, GVN President Emeritus and Senior Associate Dean for Research in Global Affairs at University of South Florida Health’s Morsani College of Medicine, USA, highlighted the importance of the collaboration: “GVN’s role to enhance global efforts is critical in identifying research gaps and facilitating action to fill those gaps. GVN is uniquely prepared to quickly engage our members and provide expertise and on-the-ground support to mitigate the growing MPOX threat. We are pleased to catalyze and facilitate alliances to prepare and protect humankind from viral threats.”

GVN’s Viral Detection and Control Action Committee will convene a critical meeting on August 22 at 11 AM EDT | 5 PM CET, with WHO’s MPOX Task Force lead, Lorenzo Subissi, PhD, who will provide updates and garner support from GVN experts.

About the Global Virus Network (GVN)
The GVN is essential and critical in the preparedness, defense, and first research response to emerging, existing, and unidentified viruses that pose a clear and present threat to public health. Working in close coordination with established national and international institutions, the GVN is a coalition comprised of eminent human and animal virologists from 80+ Centers of Excellence and Affiliates in 40+ countries, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines, and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues, and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org.


For more information or to join GVN’s efforts, please contact Linman Li at Linmanli@gvn.org.

Primary Logo

source: Global Virus Network

《說說心理話》青少年自殺率上升,如何分辨求助訊號?社工分享陪伴的重要性► 即睇

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
4
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
5
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
6
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
7
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
8
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
9
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
10
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
11
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
12
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
13
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
14
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
15
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
16
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
17
一本萬利 | 2025年的五個「勿」(有片)
18
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
19
港股 | 蕭猷華:恒指春節前目標21500點
20
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
21
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
22
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
23
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
24
習近平應約與特朗普通電話,特:冀盡快與習見面
25
易經看世界 | 從乙巳年立春八字看香港前景:哪行業當旺?哪行業運滯?(有片)
26
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
27
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
28
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
29
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
30
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老